PODD (Insulet) Stock Forecast 2026 — Omnipod 5, Type-2 Expansion, and the GLP-1 Debate
Insulet (PODD) stock analysis for 2026: Omnipod 5 AID momentum, type-2 diabetes expansion, pharmacy-channel growth, GLP-1 overhang debate, and competitive risks from Tandem and Medtronic.
PODD Insulet Medical Devices